目的：探讨注射阿米卡星和卷曲霉素治疗耐多药肺结核的远近期疗效。方法对2009年1月~2014年6月收治的耐多药肺结核病例治疗方案、不良反应、远近期疗效进行分析。结果51例耐多药肺结核患者中,44例完成6~12个月注射期治疗,治疗6个月末、12个月末、24个月末痰菌阴转率分别为58．82%、52．17%、48．48%；阿米卡星组不良反应较少,疗效较好。结论注射阿米卡星或卷曲霉素6~12个月治疗耐多药肺结核方案可行,加强不良反应的监测和及时处置,可避免严重不良反应的发生。%Objective To investigate the curative effect of amikacin or capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis for 6-12 months. Methods We monitored and analyzed the treatment, adverse reactions, short and long term curative effect of multi-drug resistant pulmonary tuberculosis from January 2009 to June 2014. Results In all 51 patients with multi-drug resistant pulmonary tuberculosis, 44 cases completed 6-12 months′ injection, and the sputum negative conversion rate was 58. 82%, 52. 17% and 48. 48% respectively at the end of 6, 12 and 24 months. The amikacin group had less adverse reactions and better curative effect than the capreo-mycin group did. Conclusion Amikacin or capreomycin injection for 6-12 months is effective for multi-drug resistant tuberculosis, and the occurrence of serious adverse reactions can be avoided by monitoring of adverse reactions and timely disposal.
展开▼
